Stocks Health care ADPT
NASDAQ · Health careAdaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp brought in $298M of revenue over the twelve months to September 30, 2026, up 17.9% from a year earlier. It posted a net loss of $70.5M. In fiscal 2025 capital spending exceeded operating cash flow by $48.9M. At September 30, 2026 it held $75.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Adaptive Biotechnologies Corp
- Net worth
- Adaptive Biotechnologies Corp has a market value (market cap) of $4.8B at the latest share price, and shareholders' equity of $176.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $277M (+54.8% year on year), with a net loss of $59.5M. Over the 12 months to September 30, 2026: revenue $298M, net loss $70.5M.
- Cash flow
- In fiscal 2025 operations used $46M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Adaptive Biotechnologies Corp's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Adaptive Biotechnologies Corp does
Adaptive Biotechnologies Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ADPT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $277M | -$59.5M | -$0.39 | -$48.9M |
| 2024 | $179M | -$159.5M | -$1.08 | -$98.9M |
| 2023 | $170.3M | -$225.3M | -$1.56 | -$167M |
| 2022 | $185.3M | -$200.2M | -$1.40 | -$200.3M |
| 2021 | $154.3M | -$207.3M | -$1.48 | -$254.5M |
| 2020 | $98.4M | -$146.2M | -$1.11 | -$168.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ADPT ranks in Health care
Latest SEC filings
What Adaptive Biotechnologies Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 11% to $83.9M versus the same quarter last year; diluted EPS $0.02 versus $0.06.
- November 4, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 22% to $71.6M versus the same quarter last year; diluted EPS -$0.25 versus -$0.17.
- July 29, 2026
- June 22, 2026
- June 15, 2026Other event 8-K
- June 9, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 5, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 35% to $70.9M versus the same quarter last year; diluted EPS -$0.13 versus -$0.20.
- May 5, 2026
Insider trades
What the people running Adaptive Biotechnologies Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $31.7M worth of shares in the last 90 days and bought none on the open market. 40% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 6, 2026 | Rubinstein JuliePresident and COO | Exercised options | 11,881 | $144.2K |
| November 6, 2026 | Rubinstein JuliePresident and COO | Soldpre-planned (10b5-1) | 8,400 | $229.5K |
| November 6, 2026 | Rubinstein JuliePresident and COO | Soldpre-planned (10b5-1) | 3,481 | $97.1K |
| November 5, 2026 | Rubinstein JuliePresident and COO | Exercised options | 11,881 | $144.2K |
| November 5, 2026 | Rubinstein JuliePresident and COO | Soldpre-planned (10b5-1) | 5,926 | $154.7K |
| November 5, 2026 | Rubinstein JuliePresident and COO | Soldpre-planned (10b5-1) | 5,455 | $146.6K |
| November 5, 2026 | Rubinstein JuliePresident and COO | Soldpre-planned (10b5-1) | 500 | $13.9K |
| November 4, 2026 | Rubinstein JuliePresident and COO | Exercised options | 11,881 | $144.2K |
Who owns ADPT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Viking Global Investors LP13G, passive with 7 related filers | 18.8% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 300 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Viking Global Investors LP | 29,993,708 | 0 |
| BlackRock, Inc. | 15,139,159 | +1,836,134 |
| Vanguard Capital Management LLC | 6,403,587 | +309,443 |
| Wellington Management Group Llp | 5,911,366 | +2,053,944 |
| Vanguard Portfolio Management LLC | 5,476,231 | +984,757 |
| D. E. Shaw & Co., Inc. | 4,625,859 | +2,660,249 |
| Westfield Capital Management Co LP | 4,267,645 | -1,169,073 |
| Geode Capital Management, LLC | 3,641,837 | +5,783 |
| State Street Corp | 3,458,388 | +231,143 |
| Invesco Ltd. | 3,094,011 | -1,356,055 |
| Goldman Sachs Group Inc | 2,984,227 | -257,850 |
| Driehaus Capital Management LLC | 2,527,703 | +777,102 |
| Arrowstreet Capital, Limited Partnership | 2,524,620 | +529,418 |
| Nuveen, LLC | 2,366,155 | +1,061,995 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2,182,326 | -505,755 |
| Fred Alger Management, LLC | 2,092,284 | +29,138 |
| ARK Investment Management LLC | 2,090,306 | -2,663 |
| Nomura Asset Management International Inc. | 1,889,188 | +8,005 |
| Aristotle Atlantic Partners, LLC | 1,838,513 | +124,167 |
| Bank of America Corp | 1,730,044 | +502,127 |
Insiders
11 insiders reported holding 4,717,631 shares in total, about $142.8M at the last price.
| Holder | Shares |
|---|---|
| Robins Chad MCEO and Chairman, Director | 2,180,518 |
| Robins Harlan SChief Scientific Officer | 812,058 |
| Bobulsky SusanChief Commercial Officer, MRD | 389,350 |
| Rubinstein JuliePresident and COO | 377,802 |
| Piskel KyleChief Financial Officer | 256,725 |
| Benzeno SharonChief Commercial Ofc Imm Med | 221,278 |
| Lo FrancisChief People Officer | 220,867 |
| Neupert Peter MDirector | 130,625 |
| Owen Katey EinterzDirector | 66,100 |
| Hershberg RobertDirector | 46,683 |
Questions about ADPT
What does Adaptive Biotechnologies Corp do?
Adaptive Biotechnologies Corp is a company in the Health care sector, listed on NASDAQ as ADPT. Its shares trade on NASDAQ under the ticker ADPT.
What is Adaptive Biotechnologies Corp's net worth?
Adaptive Biotechnologies Corp has a market value (market cap) of $4.8B at the latest share price, and shareholders' equity of $176.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Adaptive Biotechnologies Corp profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $70.5M on revenue of $298M.
How much revenue does Adaptive Biotechnologies Corp make?
Over the twelve months to September 30, 2026 Adaptive Biotechnologies Corp reported revenue of $298M. That is 17.9% more than a year earlier.
When did Adaptive Biotechnologies Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
When is Adaptive Biotechnologies Corp's next earnings report?
Adaptive Biotechnologies Corp's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ADPT with
Follow ADPT
Get an email when Adaptive Biotechnologies Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Adaptive Biotechnologies Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.